Textbook of Personalized Medicine - Second Edition [2015]

138

Table 4.9 (continued)

Drug Therapeutic area Gene Referenced subgroup
Mipomersen Endocrinology LDLR Homozygous familial
hypercholesterolemia
and LDL receptor
mutation defi cient
Modafi nil Psychiatry CYP2D6 CYP2D6 poor metabolizers
Mycophenolic Acid Transplantation HPRT1 HGPRT defi cient
Nalidixic Acid Infectious diseases G6PD G6PD defi cient
Nefazodone Psychiatry CYP2D6 CYP2D6 poor metabolizers
Nilotinib (1) Oncology BCR/ABL1 Philadelphia chromosome
(t(9 :22)) positive
Nilotinib (2) Oncology UGT1A1 UGT1A1*28 allele
homozygotes
Nitrofurantoin Infectious diseases G6PD G6PD defi cient
Nortriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers
Ofatumumab Oncology MS4A1 CD20 positive
Omacetaxine Oncology BCR/ABL1 BCR-ABL T315I
Omeprazole Gastroenterology CYP2C19 CYP2C19 poor
metabolizers
Panitumumab (1) Oncology EGFR EGFR protein expression
positive
Panitumumab (2) Oncology KRAS KRAS codon 12 and 13
mutation negative
Pantoprazole Gastroenterology CYP2C19 CYP2C19 poor
metabolizers
Paroxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers
PEG-3,350, Na 2 So 4 ,
NaCl, KCl, sodium
ascorbate

Gastroenterology G6PD G6PD defi cient

Peginterferon alfa-2b Infectious diseases IFNL3 IL28B rs12979860 T allele
carriers
Pegloticase Rheumatology G6PD G6PD defi cient
Perphenazine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Pertuzumab Oncology ERBB2 HER2 protein
overexpression positive
Phenytoin Neurology HLA-B HLA-B*1,502 allele
carriers
Pimozide Psychiatry CYP2D6 CYP2D6 poor metabolizers
Ponatinib Oncology BCR/ABL1 Philadelphia chromosome
(t(9;22)) positive, BCR
–ABL T315I mutation
Prasugrel Cardiology CYP2C19 CYP2C19 poor
metabolizers
Pravastatin Endocrinology LDLR Homozygous familial
hypercholesterolemia
and LDL receptor
defi cient
Primaquine Infectious diseases G6PD G6PD defi cient
(continued)

4 Pharmacogenetics